Biochem. J. (2010) **427**, 369–376 (Printed in Great Britain) doi:10.1042/BJ20100074

online data

SUPPLEMENTARY ONLINE DATA

Isolation and characterization of selective and potent human Fab inhibitors directed to the active-site region of the two-component NS2B–NS3 proteinase of West Nile virus

Sergey A. SHIRYAEV*, Ilian A. RADICHEV*, Boris I. RATNIKOV*, Alexander E. ALESHIN*, Katarzyna GAWLIK*, Boguslaw STEC*, Christian FRISCH†, Achim KNAPPIK† and Alex Y. STRONGIN*[1]

*Inflammatory and Infectious Disease Center, The Sanford–Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, U.S.A., and †AbD Serotec, Lena-Christ-Strasse 48, 82152 Martinsried/Planegg, Germany



Figure S1 ELISA of the recombinant Fab antibodies with NS2B–NS3pro K48A and NS2B–NS3pro H51A constructs

[1] To whom correspondence should be addressed (email strongin@burnham.org).



Figure S2 Selected antibodies efficiently inhibit the catalytic activity of WNV NS2B–NS3pro

Before the addition of the Pyr-RTKR–AMC substrate (25 μM), the purified WNV proteinase (10 nM) was co-incubated for 30 min with increasing concentrations of the antibodies. The residual activity was then monitored continuously at $\lambda_{ex} = 360$ nm and $\lambda_{em} = 465$ nm to determine the initial velocity of the reactions. The untreated proteinase was used as a control and its activity was counted as 100%. –, no antibody; Ab, antibody.

Received 11 January 2010/11 February 2010; accepted 16 February 2010
Published as BJ Immediate Publication 16 February 2010, doi:10.1042/BJ20100074